Citigroup’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.72M | Buy |
215,043
+74,379
| +53% | +$1.02M | ﹤0.01% | 2397 |
|
|
2026
Q1 | $1.75M | Sell |
140,664
-139,814
| -50% | -$1.88M | ﹤0.01% | 2752 |
|
|
2025
Q4 | $3.53M | Sell |
280,478
-2,384
| -0.8% | -$27.3K | ﹤0.01% | 2266 |
|
|
2025
Q3 | $2.83M | Buy |
282,862
+101,166
| +56% | +$908K | ﹤0.01% | 2385 |
|
|
2025
Q2 | $1.47M | Buy |
181,696
+32,120
| +21% | +$242K | ﹤0.01% | 2915 |
|
|
2025
Q1 | $1.25M | Sell |
149,576
-23,539
| -14% | -$196K | ﹤0.01% | 3090 |
|
|
2024
Q4 | $1.37M | Buy |
173,115
+20,664
| +14% | +$173K | ﹤0.01% | 3113 |
|
|
2024
Q3 | $1.27M | Buy |
152,451
+80,068
| +111% | +$626K | ﹤0.01% | 3064 |
|
|
2024
Q2 | $460K | Buy |
72,383
+6,254
| +9% | +$39.7K | ﹤0.01% | 3450 |
|
|
2024
Q1 | $401K | Buy |
66,129
+19,137
| +41% | +$108K | ﹤0.01% | 3692 |
|
|
2023
Q4 | $285K | Buy |
46,992
+46,931
| +76,936% | +$209K | ﹤0.01% | 3745 |
|
|
2023
Q3 | $257 | Sell |
61
-36,242
| -100% | -$135K | ﹤0.01% | 5292 |
|
|
2023
Q2 | $113K | Buy |
36,303
+32,054
| +754% | +$68.3K | ﹤0.01% | 4188 |
|
|
2023
Q1 | $5.91K | Sell |
4,249
-671
| -14% | -$1.34K | ﹤0.01% | 4898 |
|
|
2022
Q4 | $9.79K | Sell |
4,920
-931
| -16% | -$2.09K | ﹤0.01% | 4848 |
|
|
2022
Q3 | $11K | Sell |
5,851
-80,918
| -93% | -$227K | ﹤0.01% | 4947 |
|
|
2022
Q2 | $276K | Buy |
86,769
+73,169
| +538% | +$265K | ﹤0.01% | 3653 |
|
|
2022
Q1 | $57K | Sell |
13,600
-17,582
| -56% | -$77.9K | ﹤0.01% | 4666 |
|
|
2021
Q4 | $149K | Sell |
31,182
-11,560
| -27% | -$57.6K | ﹤0.01% | 4522 |
|
|
2021
Q3 | $228K | Buy |
42,742
+25,740
| +151% | +$130K | ﹤0.01% | 4056 |
|
|
2021
Q2 | $87K | Buy |
17,002
+4,076
| +32% | +$23.2K | ﹤0.01% | 4567 |
|
|
2021
Q1 | $87K | Sell |
12,926
-15,393
| -54% | -$85.3K | ﹤0.01% | 4429 |
|
|
2020
Q4 | $130K | Sell |
28,319
-6,199
| -18% | -$27.5K | ﹤0.01% | 5321 |
|
|
2020
Q3 | $134K | Buy |
34,518
+5,550
| +19% | +$23.7K | ﹤0.01% | 4894 |
|
|
2020
Q2 | $138K | Sell |
28,968
-6,418
| -18% | -$26.4K | ﹤0.01% | 5303 |
|
|
2020
Q1 | $123K | Buy |
35,386
+421
| +1% | +$1.78K | ﹤0.01% | 5172 |
|
|
2019
Q4 | $169K | Buy |
34,965
+21,253
| +155% | +$73.9K | ﹤0.01% | 5331 |
|
|
2019
Q3 | $40K | Sell |
13,712
-118,059
| -90% | -$412K | ﹤0.01% | 6263 |
|
|
2019
Q2 | $945K | Buy |
131,771
+119,578
| +981% | +$1.22M | ﹤0.01% | 3692 |
|
|
2019
Q1 | $173K | Buy |
12,193
+13
| +0.1% | +$172 | ﹤0.01% | 5237 |
|
|
2018
Q4 | $165K | Sell |
12,180
-22,394
| -65% | -$404K | ﹤0.01% | 5214 |
|
|
2018
Q3 | $767K | Sell |
34,574
-38,108
| -52% | -$802K | ﹤0.01% | 3788 |
|
|
2018
Q2 | $1.19M | Buy |
+72,682
| New | +$1.28M | ﹤0.01% | 3169 |
|
Other funds holding AMRX
TGA
RCMNY
Citigroup's AMRX Position: Q2 2026 in Review
Citigroup increased its Amneal Pharmaceuticals (AMRX) stake by 53% in Q2 2026, buying an estimated $1.02M and bringing the position to 215,043 shares worth $3.72M. The position accounts for ﹤0.01% of the portfolio, ranked #2397.
Citigroup first reported a position in AMRX in Q2 2018 and has held it in 33 quarters since. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.
- Citigroup held 215,043 shares of Amneal Pharmaceuticals worth $3.72M as of Q2 2026.
- Citigroup bought 74,379 Amneal Pharmaceuticals shares in Q2 2026, an estimated $1.02M.
- Amneal Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2397 holding.
- Citigroup first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.